Novabiotics - a leading clinical-stage biotechnology company
Novabiotics about us Novabiotics clinical studies Novabiotics pipeline Novabiotics our news Novabiotics contact
Date posted: 5 December 2023

UK 20 Year Vision for Antimicrobial Resistance

Deborah O’Neil, NovaBiotics CEO commented on today’s announcement: “AMR continues to pose a massive global health and socio-economic threat of a scale that cannot be underestimated or ignored. The UK Government’s continued commitment to mitigating this crisis, as set out in the incentives and plans announced today, is very welcome. The UK has always been recognised as a leader in the fight against AMR and the strategy announced today supports and is directly relevant to NovaBiotics’ discovery and development of new classes of antibacterial and antifungal medicines which not only act against microbes that are already resistant to existing treatments, but which work in such a way as to prevent resistance developing in microbes in the future. We look forward to continuing to be part of the AMR community in the UK and the global impact of the Government’s announcement today.